Alfacell Corporation

Type: Public
On the web: http://www.alfacell.com
Employees: 15
Employee growth: 0.0%

Development-stage Alfacell may kiss a few frogs in hopes one will transform into a princely product. The biotechnology firm has isolated proteins from Northern Leopard frog eggs and embryos as possible therapies for cancerous tumors that have become resistant to chemotherapy. The company's lead drug candidate, Onconase, is in late-stage clinical trials to treat mesothelioma, a cancer afflicting the lungs and stomach caused by exposure to asbestos. Alfacell is researching applications for Onconase and other amphibian proteins for applications in other areas of oncology, including small-cell lung cancer, as well as infectious diseases that include HIV.

Key numbers for fiscal year ending July, 2009:
Sales: $0.0M
Net income: ($4.5)M

Officers:
Chairman: David Sidransky
President, CEO, and CFO: Charles Muniz
SVP Commercial Development and Operations: Andrew P. Aromando

Competitors:
Eli Lilly
ImmunoGen
Merck